Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions
Neurochemical Research · 2025
DOI: 10.1007/s11064-025-04608-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2025. Verfasst von Julianna Roeser und 12 weiteren Autor:innen. Beteiligte Einrichtung: Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Tox…. Hauptthemen laut MEDLINE: Fluoxetine, Methylphenidate, Selective Serotonin Reuptake Inhibitors, Inflammation. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methylphenidate (MP) is commonly prescribed to treat attention deficit hyperactivity disorder (ADHD). ADHD and depression are often comorbid, leading to simultaneous use of serotonin reuptake inhibitors (SSRIs), such as Fluoxetine (FLX). Previous studies have shown MP increases microglial activation, which has been linked to neuroinflammation, but little is known about these two medications in combination. To address this gap in our knowledge, 3-week-old male Sprague Dawley rats were randomly assigned into four groups receiving either water, MP, FLX, or MP + FLX orally using a previously established dosing regimen. After four weeks of treatment the animal’s brains were collected for in vitro [ 3 H] PK11195 autoradiography. Chronic treatment with MP and MP + FLX resulted in significantly increased [ 3 H] PK11195 binding in somatosensory regions including the cortex limbs somatosensory (S(Limbs)), facial somatosensory (S(Face)), dorsal caudate putamen (D CPU), and ventral caudate putamen (V CPU). Chronic treatment with MP increased microglial activation in specific brain regions; however, these effects were not amplified by co-administration with fluoxetine. These findings emphasize the importance of further investigating the interactions between SSRIs and MP, particularly as their combined use becomes more prevalent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University…
- Department of Psychology, City University of New York, Queens, NY, USA.
- Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
- Division of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, 91766, USA.
- Department of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, NY, USA.
Zitieren
APA
Roeser, J., Lu, H., Lantry, A. M., Hoerner, C., Lagamjis, G., Klein, S., Ahmed, R., Elman, I., Pinhasov, A., Blum, K., Hadjiargyrou, M., Komatsu, D. E., & Thanos, P. K. (2025). Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions. Neurochemical Research. https://doi.org/10.1007/s11064-025-04608-3
Vancouver
Roeser J, Lu H, Lantry AM, Hoerner C, Lagamjis G, Klein S, et al. Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions. Neurochemical Research. 2025. doi:10.1007/s11064-025-04608-3
BibTeX
@article{Roeser2025,
author = {Roeser, Julianna and Lu, Huy and Lantry, Abigail M and Hoerner, Caleigh and Lagamjis, George and Klein, Shannon and Ahmed, Rania and Elman, Igor and Pinhasov, Albert and Blum, Ken and Hadjiargyrou, Michael and Komatsu, David E and Thanos, Panayotis K},
title = {Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions},
journal = {Neurochemical Research},
year = {2025},
doi = {10.1007/s11064-025-04608-3}
}
EUVIMED